Literature DB >> 7515024

Ectopic expression of c-kit in small-cell lung cancer.

T Hida1, R Ueda, Y Sekido, K Hibi, R Matsuda, Y Ariyoshi, T Sugiura, T Takahashi, T Takahashi.   

Abstract

Accumulating evidence suggests that c-kit plays an important role in the regulation of growth of at least 3 lineages of stem cells, while only very limited data are available on the development of human solid tumors. Our recent studies have shown that c-kit transcripts are expressed in a very restricted sub-set of human solid tumors such as small-cell lung cancer (SCLC). We have also conducted an immunohistological study on in situ localization of the c-kit protein in various human solid tumors as well as in corresponding fetal and adult normal tissues. No c-kit expression was detected in normal bronchial epithelial cells or pneumocytes in lung parenchyma of human fetal and adult specimens, indicating that the c-kit protein is aberrantly expressed in lung-cancer cells. We also found that significant chemotactic response as well as moderate in vitro cell growth occurred in SCLC cell lines upon addition of recombinant human stem-cell factor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515024     DOI: 10.1002/ijc.2910570723

Source DB:  PubMed          Journal:  Int J Cancer Suppl        ISSN: 0898-6924


  9 in total

1.  A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain.

Authors:  L P Lam; R Y Chow; S A Berger
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

2.  A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors.

Authors:  Jin-Ock Kim; Kwang-Hyeok Kim; Eun Ji Baek; Bomi Park; Min Kyung So; Byoung Joon Ko; Han-Jik Ko; Sang Gyu Park
Journal:  Mol Oncol       Date:  2021-08-29       Impact factor: 6.603

3.  CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas.

Authors:  Giuseppe Pelosi; Michele Masullo; Maria Elena Leon; Giulia Veronesi; Lorenzo Spaggiari; Felice Pasini; Angelica Sonzogni; Antonio Iannucci; Enrica Bresaola; Giuseppe Viale
Journal:  Virchows Arch       Date:  2004-09-16       Impact factor: 4.064

4.  Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.

Authors:  Ying Cheng; Qiming Wang; Kai Li; Jianhua Shi; Ying Liu; Lin Wu; Baohui Han; Gongyan Chen; Jianxing He; Jie Wang; Donghua Lou; Hao Yu; Shanchun Wang; Haifeng Qin; Xiaoling Li
Journal:  Br J Cancer       Date:  2021-05-18       Impact factor: 7.640

5.  Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line.

Authors:  Giuseppe Pirozzi; Virginia Tirino; Rosa Camerlingo; Renato Franco; Aantonello La Rocca; Eleonora Liguori; Nicola Martucci; Francesca Paino; Nicola Normanno; Gaetano Rocco
Journal:  PLoS One       Date:  2011-06-30       Impact factor: 3.240

6.  Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.

Authors:  Helge Siemens; Rene Jackstadt; Markus Kaller; Heiko Hermeking
Journal:  Oncotarget       Date:  2013-09

7.  Altered expression of cytokeratin 7 and CD117 in transitional mucosa adjacent to human colorectal cancer.

Authors:  Hideaki Kigasawa; Masachika Fujiwara; Jun Ishii; Tomohiro Chiba; Yuichi Terado; Hiroaki Shimoyamada; Makoto Mochizuki; Osamu Kitamura; Hiroshi Kamma; Yasuo Ohkura
Journal:  Oncol Lett       Date:  2017-05-11       Impact factor: 2.967

8.  Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer.

Authors:  Kwang-Hyeok Kim; Jin-Ock Kim; Jeong-Yang Park; Min-Duk Seo; Sang Gyu Park
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

9.  Stem cell growth factor receptor in canine vs. feline osteosarcomas.

Authors:  Birgitt Wolfesberger; Andrea Fuchs-Baumgartinger; Juraj Hlavaty; Florian R Meyer; Martin Hofer; Ralf Steinborn; Christiane Gebhard; Ingrid Walter
Journal:  Oncol Lett       Date:  2016-08-12       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.